β2‐Adrenoreceptor Agonists, Montelukast, and Parkinson Disease Risk
β2‐Adrenoreceptor Agonists, Montelukast, and Parkinson Disease Risk
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Stockholm, SE · Author affiliation
Department of Medical Epidemiology and Biostatistics Karolinska Institute Stockholm SwedenLocation evidence
Örebro, SE · Author affiliation
Department of Pediatrics Örebro University Hospital Örebro SwedenLocation evidence
London, GB · Author affiliation
MRC Unit for Lifelong Health and Ageing at UCL University College London London UKLocation evidence
Los Angeles, US · Author affiliation
Department of Psychology University of Southern California Los Angeles CA USALocation evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
ObjectiveThis study was undertaken to examine the association between montelukast use, β2‐adrenoreceptor (β2AR) agonist use, and later Parkinson disease (PD).MethodsWe ascertained use of β2AR agonists (430,885 individuals) and montelukast (23,315 individuals) from July 1, 2005 to June 30, 2007, and followed 5,186,886 PD‐free individuals from July 1, 2007 to December 31, 2013 for incident PD diagnosis. We estimated hazard ratios and 95% confidence intervals using Cox regressions.ResultsWe observed 16,383 PD cases during on average 6.1 years of follow‐up. Overall, use of β2AR agonists and montelukast were not related to PD incidence. A 38% lower PD incidence was noted among high‐dose montelukast users when restricted to PD registered as the primary diagnosis.InterpretationOverall, our data do not support inverse associations between β2AR agonists, montelukast, and PD. The prospect of lower PD incidence with high‐dose montelukast exposure warrants further investigation, especially with adjustment for high‐quality data on smoking. ANN NEUROL 2023;93:1023–1028